ARDX Stock Analysis: Ardelyx | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 782m USD | 12M Return: -41.3% | US0396971071 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 13.3M
Qual. Beats: 0
Rev. Trend: 94.5%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ardelyx, Inc. is a U.S.-based biopharmaceutical company that discovers, develops, and commercializes small molecule therapies addressing unmet medical needs, primarily in gastrointestinal and renal therapeutic areas. The company markets two FDA-approved products: IBSRELA, indicated for irritable bowel syndrome with constipation, and XPHOZAH, a phosphate absorption inhibitor approved to reduce serum phosphorus in adults with chronic kidney disease on dialysis.
Operating within the biotechnology sub-industry, Ardelyx follows a focused commercial model centered on specialty launches in niche indications, a common approach among small-cap biotechs that rely on concentrated physician targeting rather than broad primary-care promotion. The company is headquartered in Waltham, Massachusetts, was incorporated in 2007, and was originally known as Nteryx, Inc. before adopting its current name in June 2008.
- XPHOZAH sales trajectory uncertain after CMS reimbursement changes
- IBSRELA prescription growth drives IBS-C segment revenue
- Cash burn raises capital allocation and dilution concerns
| Net Income: -55.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA 3.09 > 1.0 |
| NWC/Revenue: 68.69% < 20% (prev 69.88%; Δ -1.20% < -1%) |
| CFO/TA -0.03 > 3% & CFO -17.3m > Net Income -55.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.34 > 1.5 & < 3 |
| Outstanding Shares: last quarter (248.1m) vs 12m ago 3.39% < -2% |
| Gross Margin: 93.96% > 18% (prev 84.48%; Δ 9.48% > 0.5%) |
| Asset Turnover: 86.49% > 50% (prev 82.73%; Δ 3.76% > 0%) |
| Interest Coverage Ratio: -1.02 > 6 (EBIT TTM -28.0m / Interest Expense TTM 27.4m) |
| A: 0.54 (Total Current Assets 441.9m - Total Current Liabilities 132.2m) / Total Assets 575.9m |
| B: -1.74 (Retained Earnings -1.00b / Total Assets 575.9m) |
| C: -0.05 (EBIT TTM -28.0m / Avg Total Assets 521.3m) |
| D: 0.35 (Book Value of Equity 149.0m / Total Liabilities 426.9m) |
| Altman-Z'' = -2.13 = D |
| DSRI: 1.37 (Receivables 100.4m/62.6m, Revenue 450.9m/386.1m) |
| GMI: 0.90 (GM 84.48% / 93.96%) |
| AQI: 0.99 (AQ_t 0.23 / AQ_t-1 0.23) |
| SGI: 1.17 (Revenue 450.9m / 386.1m) |
| TATA: -0.07 (NI -55.7m - CFO -17.3m) / TA 575.9m) |
| Beneish M = -2.70 (Cap -4..+1) = A |
As of November 05, 2026, the stock is trading at USD 3.29 with a total of 10,583,598 shares traded. Over the past week, the price has changed by +6.13%, over one month by -2.95%, over three months by -34.33% and over the past year by -41.25%.
Current recommended Stop Loss: 3.10 (which is 5.8% or 1.5 ATR below the current price).
Ardelyx has received a consensus analysts rating of 4.91. Therefore, it is recommended to buy ARDX.
- StrongBuy: 10
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12.8 | 289.1% |
P/E Forward = 8.643
P/S = 1.735
P/B = 5.2413
P/EG = -0.08
Revenue TTM = 450.9m USD
EBIT TTM = -28.0m USD
EBITDA TTM = -24.7m USD
Long Term Debt = 251.8m USD (from longTermDebt, last quarter)
Short Term Debt = 1.54m USD (from shortTermDebt, last quarter)
Debt = 260.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 4.37m
Net Debt = -21.3m USD (calculated: Debt 260.6m - CCE 281.8m)
Enterprise Value = 761.0m USD (782.3m + Debt 260.6m - CCE 281.8m)
Interest Coverage Ratio = -1.02 (Ebit TTM -28.0m / Interest Expense TTM 27.4m)
EV/FCF = 446.4x (Enterprise Value 761.0m / FCF TTM 1.71m)
FCF Yield = 0.22% (FCF TTM 1.71m / Enterprise Value 761.0m)
FCF Margin = 0.38% (FCF TTM 1.71m / Revenue TTM 450.9m)
Net Margin = -12.35% (Net Income TTM -55.7m / Revenue TTM 450.9m)
Gross Margin = 93.96% ((Revenue TTM 450.9m - Cost of Revenue TTM 27.2m) / Revenue TTM)
Gross Margin QoQ = none% (prev 94.91%)
Tobins Q-Ratio = 1.32 (Enterprise Value 761.0m / Total Assets 575.9m)
Interest Expense / Debt = 10.53% (Interest Expense 27.4m / Debt 260.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -22.2m (EBIT -28.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.59 (Total Current Assets 441.9m / Total Current Liabilities 170.6m)
Debt / Equity = 1.75 (Debt 260.6m / totalStockholderEquity, last quarter 149.0m)
Debt / EBITDA = 0.86 (negative EBITDA) (Net Debt -21.3m / EBITDA -24.7m)
Debt / FCF = -12.48 (Net Debt -21.3m / FCF TTM 1.71m)
Total Stockholder Equity = 154.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.68% (Net Income -55.7m / Total Assets 575.9m)
RoE = -36.00% (Net Income TTM -55.7m / Total Stockholder Equity 154.7m)
RoCE = -6.90% (EBIT -28.0m / Capital Employed (Equity 154.7m + L.T.Debt 251.8m))
RoIC = -5.24% (negative operating profit) (NOPAT -22.2m / Invested Capital 422.7m)
WACC = 6.93% (E(782.3m)/V(1.04b) * Re(6.47%) + D(260.6m)/V(1.04b) * Rd(10.53%) * (1-Tc(0.21)))
Discount Rate = 6.47% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 90.69 | Cagr: 2.81%
[DCF] Terminal Value 75.44% ; FCFF base≈1.71m ; Y1≈1.71m ; Y5≈1.81m
[DCF] Fair Price = 0.19 (EV 28.2m - Net Debt -21.3m = Equity 49.5m / Shares 258.2m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.37 | # QB: 0
Revenue Correlation: 94.46 | Revenue CAGR: 64.48% | SUE: -0.10 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.02 | Chg30d=N/A | Revisions=-25% | Analysts=8
EPS next Quarter (2027-03-31): EPS=-0.04 | Chg30d=N/A | Revisions=-25% | Analysts=4
EPS current Year (2026-12-31): EPS=-0.19 | Chg30d=+0.64% | Revisions=+25% | GrowthEPS=+28.1% | GrowthRev=+18.4%
EPS next Year (2027-12-31): EPS=0.29 | Chg30d=-1.67% | Revisions=-25% | GrowthEPS=+257.3% | GrowthRev=+28.8%
[Analyst] Revisions Ratio: -29% (up=1, down=3)